Gut microbiota in patients with arterial hypertension and metabolic syndrome
https://doi.org/10.31146/1682-8658-ecg-200-4-87-93
Abstract
In recent years, attention has been growing to assessing the role of the state of intestinal microbiocenosis in the development of cardiovascular diseases, including arterial hypertension (AH) and metabolic syndrome (MS), the individual components of which are more or less associated with the state of the microbiota. In this regard, we made an attempt to clarify the features of the intestinal microbiota in hypertensive patients with MS in a comparative aspect with those with isolated hypertension. A microbiological study of feces was carried out in 86 patients, of which 46 with AH (comparison group) and 40 with AH and MS (main group). The microbiota of patients’ faeces was investigated using the classical bacteriological method and the biochemical method for express diagnostics of dysbiosis. For fecal microbiota in AH with MS, in comparison with AH, a lower release of representatives of normal microfl ora (bacteroids, latobacilli, bifi dobacteria), with the exception of Escherichia coli, is characteristic, more frequent excretion of facultative microfl ora (enterococci, Klebsiella, peptostreptococcus, staphylococcus protrusion)., II and III degree of dysbiosis (versus I and II with hypertension). The study revealed that the composition of the intestinal microbiota in patients with hypertension is associated with MS both in terms of a decrease in individual representatives of normal microfl ora and in terms of the greater presence and appearance of new representatives of opportunistic microfl ora, forming a high degree of dysbiosis in hypertensive patients with MS.
About the Authors
M. V. Yakovleva
Tver State Medical University
Russian Federation
Russian Federation
Margarita V. Yakovleva, Assistant, Department of Internal Medicine
4, Sovetskaya St., Tver, 170100
L. E. Smirnova
Tver State Medical University
Russian Federation
Russian Federation
Ludmila E. Smirnova, Doctor of Medical Sciences Sciences, Associate Professor, Head of the Department of Internal Medicine
4, Sovetskaya St., Tver, 170100
Yu. V. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
Yulia V. Chervinets, Dr. med. Sciences, Professor of the Department of Microbiology, Virology with a course in immunology
4, Sovetskaya St., Tver, 170100
V. M. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
Vacheslav M. Chervinets, Dr. med. Sci., Professor, Head of the Department of Microbiology, Virology with the Course of Immunology
4, Sovetskaya St., Tver, 170100
References
1. Gubergrits N.B., Belyaeva N. V., Klochkov A. E. Metabolic syndrome: how to avoid polypharmacy? Moscow. Prima Print Publ., 2017. 96 P.
2. Akimova E.V, Akimov M. Yu, Petelina T. I. Prevalence of metabolic syndrome components in men of an open urban population accc to diff erent assessment criteria. Th e Russian Journal of Preventive Medicine. 2021; 24(2): 37–43. (In Russ.). doi: 10.17116/profmed20212402137
3. Sjostrom L., Rissanen A., Andersen T., et al. Randomized, placebo- controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352: 167–172. doi: 10.1016/s0140–6736(97)11509–4
4. Chrysohoou C., Pitsavos C., Skoumas J., et al. The emerging anti-infl ammatory role of HDL-cho- lesterol, illustrated in cardiovascular disease free population; the ATTICA study. Int J Cardiol. 2007;122(1):29–33. doi: 10.1016/j.ijcard.2006.11.010
5. Drapkina O.M., Kaburova A. N. Gut microbiota – a new companion on the path of cardiovascular diseases progression: surprising roles of long-time neighbors. Rational Pharmacotherapy in Cardiology. 2016;12(1):66–71. (In Russ.) doi: 10.20996/1819–6446–2016–12–1–66–71
6. Khavkin A.I., Komarova O. N. Saccharomyces boulardii infl uence over human microbiota. Literature review. Experimental and Clinical Gastroenterology. 2017;(6):126–132. (In Russ.)
7. Osadchuk A.M., Davydkin I. L., Gricenko T. A., Lebedeva E. A., Petrushin A. E. The role of the microbiota of the gastrointestinal tract in the development of diseases of internal organs. Experimental and Clinical Gastroenterology. 2018;(5):133–139. (In Russ.)
8. Livzan M.A., Krolevets T. S., Mozgovoy S.l., et al. Features of intestinal microbiota disorders in the development of metabolic disorders in non-alcoholic fatty liver disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93(2):222–227. (in Russ.) doi: 10.26442/00403660.2021.02.200614
9. Chervinets V.M., Chervinets Yu.V., Serova N. E., et al. Clinical and microbiological features of patients with arterial hypertension among residents of the Tver region. Modern problems of science and education. 2019;(3):111–111. (in Russ.)
10. Koshelskaya O.A, Kharitonova O.A, Kologrivova I. V., et al. Metabolic, infl ammatory and imaging biomarkers in evaluation of coronary atherosclerosis severity in patients with coronary artery disease and diabetes mellitus type 2. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (9): 1030–1036. (in Russ.) doi: 10.26442/00403660.2021.09.201032
11. Karpunina N. S., Karpunina T. I. Gut microbiota in cardiologic patients: aggressive or defensive factor? Experimental and Clinical Gastroenterology. 2018; 156(8): 4–9. doi:10.31146/1682–8658-есд-156–8–4–9
12. Lazebnik L.B., Konev Yu. V. Historical features and semantic diffi culties of using the terms denoting multiplicity of diseases in one patient. Experimental and Clinical Gastroenterology. 2018;(6):4–9. (In Russ.)
13. Chazov I. E. Clinical guidelines. metabolic syndrome. 2013. (in Russ.) Available at: https://mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom_pdf. Access: 05.05.2021.
14. Chazov I. E. Clinical guidelines. Diagnostics and treatment of arterial hypertension. Systemic hypertension. 2019; 16 (1): (in Russ.) doi: 10.26442/20755082X.2019.1.190179
15. Industry standard “Protocol for the management of patients. Intestinal dysbacteriosis” OST 91500.11.0004–2003, approved by the Order of the Ministry of Health of the Russian Federation No. 231 of 09.06.2003. (in Russ.) Available at: https://docs.cntd.ru/document/1200119089 Access: 05.05.2021.
16. Chervinets V.M., Bondarenko V. M., Vinogradov V. F., Chervinets Yu. V. Method for determining caseinolytic activity of microorganisms in express diagnostics of intestinal dysbiosis. Patent for invention No. 2235324 dated August 25, 2004. (in Russ.)
Review
For citations:
Yakovleva M.V., Smirnova L.E., Chervinets Yu.V., Chervinets V.M. Gut microbiota in patients with arterial hypertension and metabolic syndrome. Experimental and Clinical Gastroenterology. 2022;(4):87-93. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-200-4-87-93
Views:
308
Email this article 